Motor fluctuations in Parkinson’s disease (PD) can be minimized by reducing oscillations in plasma levodopa levels [1]. One strategy proposed to achieve this is through the frequent ingestion of levodopa solution [2], although placebo-controlled studies have failed to demonstrate a meaningful difference in the profile of plasma drug levels when compared to tablets [3]. In spite of the availability of other strategies for continuous therapies that provide good management of motor fluctuations, some centres continue to use “liquid-levodopa” as a treatment option. We describe a case where this treatment was associated with severe biochemical disruption.

A 76-year-old lady with PD of nine years presented to our centre with three days of worsening mobility and an acute deterioration in mental state with a prodrome of fatigue over three weeks. Her medical history included osteoporosis, rectal ulcer, hypercholesterolaemia, cataract and glaucoma. She was afebrile and haemodynamically stable. Her cardiovascular examination was unremarkable. She had moderate delirium, severe parkinsonism and no new focal neurological signs.

Her medications included levodopa 100 mg/carbidopa 25 mg tablets (prepared as 10 tablets in 1,000 mL water with no citric acid), using the equivalent of 17 tablets per day, levodopa 200 mg/carbidopa 25 mg controlled release nocte, pramipexole 1 mg bd, omeprazole 20 mg nocte, entacapone 200 mg nocte, quetiapine controlled release 75 mg nocte, simvastatin 40 mg/ezetimibe 10 mg nocte, paracetamol 1 g bd, Macrogol 3,350 and electrolytes (MovicolTM, Norgine Pharmaceuticals, New South Wales, Australia) 2 sachets bd. The levodopa/carbidopa solution was taken as 110 mL per hour from 0500 to 2100. She consumed up to 4 sachets of MovicolTM per day by mixing 2 sachets with 250 mL of water. She drank water freely to help with her constipation, which was more troublesome the week before her presentation. She could not quantify the exact increase in fluid volume. Her estimated total daily fluid volume intake was 3.5 L.

She was managed with a 500 mL fluid restriction. The liquid levodopa was converted to tablets six times daily with twice daily pramipexole. Her mental state recovered over 4 days in line with her sodium recovering to 134 mmol/L.

This patient’s hyponatremia is consistent with a SIADH. Symptomatic hyponatremia complicating dopaminergic therapy including L-dopa/Carbidopa and dopamine agonists [4] has been described with SIADH postulated as the probable pathophysiological mechanism [5]. Dopamine has been shown to facilitate anti-diuretic hormone (ADH) release, driving the dilute urine excretion which causes hyponatraemia. Prior blockade of dopamine receptors by antagonists potentially render them supersensitive to L-dopa [6]. In our case, the previous use of quetiapine, a mild D2 receptor antagonist may be partially implicated. Furthermore, the liquid levodopa approach has been shown to result in brisk onset peak levodopa plasma concentration levels with the hourly administration regime resulting in a progressive increase in average circulating drug level. This accumulation increases the risk of adverse effects during the latter part of the day [3].

SIADH is however a rare complication of a commonly used medication. Perhaps more importantly the liquid levodopa approach requires the patient to consume excessive water volume which in the setting of hyponatraemia is likely to further distort the metabolic derangements. In this circumstance increased oral water load would be expected to suppress the renal ADH response, reducing the ability of the kidney to concentrate urine.

Additional water intake is often recommended by clinicians when treating people with PD with constipation. In this patient, the additional water load of the method of levodopa delivery was the likely trigger for her to develop this acute medical deterioration, given it had not occurred with previous treatment regimens and was easily corrected. Fluid restriction treated the SIADH despite continuing a similar dose of (regular release) levodopa tablets. High dose levodopa does not invariably cause SIADH and there are no current reports with levodopa-carbidopa intestinal gel delivery.

This case illustrates an outdated approach in the administration of levodopa that can result in a rare and long forgotten adverse outcome of the treatment which can cause significant patient morbidity and hospital admission.

Article information Continued

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.